Leukocytosis Is Associated with End Organ Damage in Chronic Myelomonocytic Leukemia (CMML) and Can be Mitigated with Cytoreductive Therapy

Conclusions: MPN-CMML is associated with EOD that includes AKI/CKD, pleural effusions, LFT abnormalities, and CVE. Those cases with a WBC >33.95cells/dL are at particularly high risk for EOD and cytoreductive therapy should be routinely considered to mitigate this risk.DisclosuresSweet: Celgene: Honoraria, Speakers Bureau; Phizer: Consultancy; BMS: Honoraria; Agios: Consultancy; Astellas: Consultancy; Jazz: Speakers Bureau; Jazz: Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; BMS: Honoraria; Phizer: Consultancy; Agios: Consultancy; Astellas: Consultancy; Celgene: Honoraria, Speakers Bureau. Sallman: Celgene: Research Funding, Speakers Bureau. List: Celgene: Research Funding. Komrokji: Novartis: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Celgene: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Novartis: Honoraria, Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Hunter, A., Al Ali, N., Mai, A., Talati, C., Kuykendall, A., Sweet, K. L., Sallman, D. A., Lancet, J. E., List, A. F., Komrokji, R. S., Padron, E. Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Poster II Source Type: research